News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Guidance
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BioNexus Gene Lab Corp director Bin Abdul Hamid Muhammad Azrul received a fully vested equity award of 32,258 common shares on August 13, 2026. The award, valued at $1.55 per share, was granted under the company’s 2025 Equity Incentive Plan for completed services, with …
BioNexus Gene Lab Corp (BGLC) director Low Jook Yuen received a fully vested stock award of 16,129 shares of common stock on August 13, 2026, for services rendered. This equity compensation, granted under the company's 2025 Equity Incentive Plan, had no cash consideration and …
CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 9.9% beneficial ownership in Bionano Genomics (BNGO) through warrants. This position, amounting to 1,307,135 shares, is subject to ownership caps of 4.99% and 9.99% for different portions of the warrants. The ownership percentage …
Company Logo Accelerating demand for clean-label food preservation, natural acidulants, and bio-based materials highlighted by ADM's fermentation scale-ups, Corbion's next-gen lactic acid technology rollouts, and bio-based citric acid expansions across Cargill and Jungbunzlauer is propelling the global market from $11.1 billion in 2026 to …
BioNTech SE Sponsored ADR (NASDAQ:BNTX) has received an average "Moderate Buy" rating from nineteen brokerages, with an average 12-month price target of $127.81. Recent analyst actions have been mixed, including an upgrade from UBS to "buy" with a $135 target, and price target reductions …
This article provides an overview of analyst ratings for three healthcare companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA), and PolyPid (PYPD). BioNano Genomics received a "Buy" rating with a $4.00 price target, while Liquidia Technologies was given a "Hold" rating and a $90.00 price …
Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 595,000 shares, representing 1.3% of Beta Bionics, Inc. (BBNX) common stock as of June 30, 2026. This stake was reported in a SCHEDULE 13G/A SEC filing, indicating shared voting and …
BioNTech has appointed Guido Oelkers, former CEO of Sobi, as its new chief executive, effective by February 1, 2027. This leadership change is a planned transition to steer BioNTech toward a diversified oncology pipeline, moving beyond its primary focus on COVID-19 vaccines. Oelkers' experience …
Sharemaestro market context Price below Trend Line 52 weeks -24.3% · Next-week setup negative 30.5%Maxim Group has reiterated its Buy rating for Bionano Genomics (BNGO.US), along with a maintained target price of $4. This indicates a continued positive outlook from the firm regarding the company's stock performance and valuation.
BofA Securities has maintained its Hold rating on Beta Bionics (BBNX.US) and increased its target price for the company's stock to $18. This adjustment reflects BofA's updated outlook for Beta Bionics.
Bionano Genomics, Inc. published its 2026 Q2 earnings call presentation. The slide deck was released in conjunction with the company's Q2 earnings call. This article was written by SA Transcripts, which publishes thousands of quarterly earnings call transcripts.
BioNTech reported Q2 2026 earnings, with total revenue down to EUR 106 million due to lower COVID-19 vaccine demand and the absence of a prior-year payment from Pfizer. The company revised its full-year revenue guidance to EUR 1.6 billion to EUR 1.9 billion, reflecting …
Beta Bionics, Inc. (BBNX) has seen its average 12-month price target raised from $20.08 to $20.31 by 11 analysts, with forecasts ranging from $14 to $30.4 per share. This new target implies a potential upside of approximately 24% from its August 10 closing price. …
BioNexus Gene Lab Corp., a Nasdaq-listed biotech firm, has become the first to adopt an Ethereum-focused treasury strategy, following Ethereum's inclusion in the U.S. "Crypto Strategic Reserve." The company released a whitepaper detailing Ethereum's advantages as a financial infrastructure asset, citing its liquidity, utility, …
Bionano Genomics Inc (BNGO) reported Q2 2026 revenue of $8.2 million, a 21% year-over-year increase, exceeding guidance, driven by record flow cell sales. Despite strong demand and increased gross margins, the company faces supply constraints for flow cells and a decline in software revenue. …
Bionano Genomics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …
Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * "Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers," said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding …
Sharemaestro market context Price below Trend Line 52 weeks -66.0% · Next-week setup negative 30.6%Search by ticker symbol or company name and select a result to open its chart.